目的：采用二维斑点追踪技术（2D-STE）检测肥厚型心肌病（Hypertrophic cardiomyopathy，HCM）患者乳头肌纵向收缩功能、同步性及位置特点。方法：收集通过经胸超声心动图诊断为HCM的患者34例，和同期健康人34例，采用STE检测乳头肌纵向应变、两乳头肌达峰值应变时间差及圆周角度，比较两组间各参数的差异。结果：HCM组患者两乳头肌圆周角度及前外侧乳头肌面积均明显大于对照组，差异有统计学意义（P＜0.05）。HCM患者乳头肌各节段及整体纵向应变均较正常对照组减低（P值均＜0.05）。HCM组患者两乳头肌应变达峰时间差值显著大于对照组，差异有统计学意义（P＜0.05）。结论：HCM患者会出现乳头肌前移，乳头肌纵向收缩功能减低且两乳头肌收缩不同步。利用2D-STE可全面评价乳头肌功能。
Abstract
Objective: To evaluate the longitudinal contractile function, synchrony and location of papillary muscle in patients with hypertrophic cardiomyopathy(HCM) with two-dimensional speckle tracking echocardiography(2D-STE). Methods: Thirty-four patients diagnosed with HCM by transthoracic echocardiography and thirty-four healthy people at the same period were collected. 2D-STE was used to evaluate the longitudinal strain of papillary muscle. The time difference between the time from the starting point of QRS to the peak strain of the two papillary muscles and the circumference angle of papillary muscle, the differences of various parameters between the two groups were compared. Results: The circumferential angle of the two papillary muscles and the area of the anterior lateral papillary muscle were significantly higher in the HCM group than in the control group(P<0.05). The segments of the papillary muscles and the overall longitudinal strain of HCM patients were lower than those of the normal control group(P<0.05). The difference in strain peak time between the two papillary muscles in the HCM group was significantly greater than that in the control group, and the difference was statistically significant(P<0.05). Conclusion: In HCM patients, the papillary muscles move forward, the longitudinal contraction function of the papillary muscles is reduced, and the contraction of the two papillary muscles is not synchronized. Papillary muscle function can be fully evaluated using 2D-STE.
关键词
心肌病 /
肥厚性 /
超声检查 /
多普勒 /
彩色
Key words
Cardiomyopathy, hypertrophic /
Ultrasonography, Doppler, color
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]Efthimiadis GK, Pagourelias ED, Hadjimiltiades S, et al. Feasibility and significance of preclinical diagnosis in hypertrophic cardiomyopathy[J]. Cardiol Rev, 2015, 23(6): 297-302.
[2]Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2014, 35(39): 2733-2779.
[3]Harrigan CJ, Appelbaum E, Maron BJ, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy[J]. Am J Cardiol, 2008, 101(5): 668-673.
[4]Levine RA, Vlahakes GJ, Lefebvre X, et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction[J]. Circulation, 1995, 91(4): 1189-1195.
[5]Baxi AJ, Restrepo CS, Vargas D, et al. Hypertrophic cardiomyopathy from A to Z: genetics, pathophysiology, imaging, and management[J]. Radiographics, 2016, 36(2): 335-354.
[6]Hensley N, Dietrich J, Nyhan D, et al. Hypertrophic cardiomyopathy: a review[J]. Anesth Analg, 2015, 120(3): 554-569.
[7]Cha JJ, Chung H, Yoon YW, et al. Diverse geometric changes related to dynamic left ventricular outflow tract obstruction without over hypertrophic cardiomyopathy[J]. Cardiovasc Ultrasound, 2014, 12(1): 23.
[8]Kwon DH, Setser RM, Thamilarasan M, et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J]. Heart, 2008, 94(10): 1295-1301.
[9]Delling FN, Sanborn DY, Levine RA, et al. Frequency and mechanism of persistent systolic anterior motion and mitral regurgitation after septal ablation in obstructive hypertrophic cardiomyopathy[J]. Am J Cardiol, 2007, 100(11): 1691-1695.
[10]Weissler-Snir A, Crean A, Rakowski H. The role of imaging in the diagnosis and management of hypertrophic cardiomyopathy[J]. Expert Rev Cardiovasc Ther, 2016, 14(1): 51-74.
[11]Sade LE. Speckle tracking strain imaging: Practical approach for application[J]. Turk Kardiyol Dern Ars, 2017, 45(2): 197-205.
[12]Luis SA, Pellikka PA. Is speckle tracking imaging ready for prime time in current echo clinical practice?[J]. Prog Cardiovasc Dis, 2018, 61(5-6): 437-445.
[13]杨性安，王刚，朱通伟，等. 二维斑点追踪技术评价肥厚型心肌病左心房功能[J]. 中国临床医学影像杂志，2012，23（12）：890-892.
[14]Tigen K, Karaahmet T, Dundar C, et al. The importance of papillary muscle dyssynchrony in predicting the severity of functional mitral regurgitation in patients with non-ischemic dilated cardiomyopathy: a two-dimensional speckle-tracking echocardiography study[J]. Eur J Echocardiogr, 2010, 11(8): 671-676.
[15]Van Garsse L, Gelsomino S, Parise O, et al. Systolic papillary muscle dyssynchrony predicts recurrence of mitral regurgitation in patients with ischemic cardiomyopathy(ICM) undergoing mitral valve repair[J]. Echocardiography, 2012, 29(10): 1191-1200.
[16]Erden M, Van Velzen HG, Menting ME, et al. Three-dimensional echocardiography for the assessment of left ventricular geometry and papillary muscle morphology in hypertrophic cardiomyopathy[J]. J Ultrasound, 2018, 21(1): 17-24.
[17]Briasoulis A, Mallikethi-Reddy S, Palla M, et al. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis[J]. Heart, 2015, 101(17): 1406-1411.
[18]Silbiger JJ. Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy: echocardiographic, pathophysiologic, and surgical insights[J]. J Am Soc Echocardiogr, 2016, 29(7): 622-639.
[19]Teo EP, Teoh JG, Hung J. Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy[J]. Curr Opin Cardiol, 2015, 30(5): 475-482.
[20]Harb SC, Griffin BP. Mitral valve disease: a comprehensive review[J]. Curr Cardiol Rep, 2017, 19(8): 73.
[21]潘文志，周达新，葛均波. 二尖瓣反流机制的新认识及其应用[J]. 中国医学前沿杂志：电子版，2017，9（10）：43-46.
[22]Jung H, Yang PS, Sung JH, et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study[J]. Thromb Hemost, 2019, 119(2): 285-293.
